Www.bmc.org



Below is a summary of some key variables from electronic medical record (EMR) abstraction available to investigators who leverage data or samples from the Prospective COVID-19 Cohort Study – Inpatient arm:Demographics AgeSex at birthGenderRace/EthnicityCityStateHousing (community/facility/incarcerated/homeless)Epidemiological Risk Factor (travel, known contact of exposure)Pregnancy StatusInsuranceHealth Maintenance Systolic Blood PressureDiastolic Blood Pressure Smoking (ever/never)Smoking (current/not current)Alcohol Abuse Injection Drug UserPolysubstance UseMethamphetamine UseMarijuana UseDiagnoses prior to admission Heart DiseaseIschemic StrokeMyocardial InfarctionHeart FailureDiabetesPeripheral Artery DiseaseHypertensionDyslipidemiaArrhythmiaChronic Kidney diseaseCardiomyopathy Chronic Obstructive Pulmonary DiseaseAsthmaMalignancyHuman Immunodeficiency VirusHepatitis C VirusHepatitis B Virus Acute Kidney InjuryAcute Kidney Injury and DialysisChronic Kidney DiseaseHistory of TransplantObesityRheumatological DiseasesLaboratoriesWhite Blood CellsWhite Blood Cell DifferentialAbsolute Neutrophil CountHematocritHemoglobinPlateletGlucoseCreatinineEstimated Glomerular Filtration RateAnion GapAlbuminAspartate TransaminaseAlanine TransaminaseTotal BilirubinTroponin I/T/CNT-proB-type Natriuretic PeptideLactic Acid DehydrogenaseC-Reactive ProteinCreatine KinaseProcalcitoninCD4 (absolute count and percent)Blood TypeResults of Viral Respiratory Panel (Influenzas)Results of Viral Respiratory Panel (Coronavirus)Results of SARS-CoV-2 AntibodiesResults of Micro Cultures (sputum, BAL, urine, blood)Pathology ReportsComprehensive Metabolic PanelProthrombin Time (PT)Partial Thromboplastin Time (PTT)International Normalized Ratio (INR)D-DimerComplement C3, C4, CH50Spot Urine Protein or Urine Protein Spot Urine Creatinine or Urine Creatinine 24-hour Urine ProteinMedications Prior to Admission Statin / Prior use of satinAnti-hypertensiveAngiotensin-converting-enzyme inhibitorsAngiotensin II Receptor BlockersAspirinSteroidsInhaled SteroidsNonsteroidal Anti-Inflammatory DrugsBronchodilatorImmunomodulatoryChemotherapyChloroquineHydroxychloroquineLopinavir/RtonavirDarunavir/Ritonavir?Darunavir/Cobicistat?Therapeutic AnticoagulationLovenoxCoumadin FondaparinuxRivaroxabanApixabanDabigatranEdoxabanCoumadin Any AntiretroviralAny Monoclonal AntibodyMedication during hospitalization Statin / Prior use of satinAnti-hypertensiveAngiotensin-converting-enzyme inhibitorsAngiotensin II Receptor BlockersAspirinSteroidsInhaled SteroidsAntibiotics Nonsteroidal Anti-inflammatory DrugsBronchodilatorImmunomodulatoryChemotherapyRemdesivirChloroquineHydroxychloroquineLopinavir/RitonavirDarunavir/Ritonavir?Darunavir/Cobicistat?Therapeutic AnticoagulationLovenoxUnfractionated HeparinFondaparinuxRivaroxabanApixabanDabigatranEdoxabanCoumadin Any AntiretroviralAny Monoclonal AntibodyImaging during hospitalization Chest Radiograph (X-Ray)Chest CTEcho (TTE/TEE)Doppler UltrasoundsClinical Symptoms/Signs Duration symptom onset to hospitalizationDuration admission to intensive care unitTemperature on admissionMax fever during hospitalization & date (longitudinal data)Body Mass IndexHypoxemia / Sp02 on day of diagnosis (longitudinal data)CongestionHeadacheCoughSore ThroatSputum ProductionFatigueHemoptysisDyspneaNausea/VomitingDiarrheaMyalgia/ArthralgiaChillsLymphadenopathyRashLoss of sense of smellLoss of sense of tasteVision ChangesConfusionDeliriumAgitationShortness of breathOutcomes during admissionAdmissionNoninvasive Ventilation Intensive Care Unit admission (Y/N) and days in ICU, days from admission to ICU transferMechanical Ventilator Use (length of ventilator status)Pressors (Y/N)MortalityNew Venous ThromboembolismNew Cerebrovascular Accident New Myocardial InfarctionNew Congestive Heart Failure ExacerbationNew MyocarditisRespiratory FailureRenal Failure (AKI requiring renal replacement therapy)Acute Kidney InjuryAcute Kidney Injury + Chronic Kidney DiseaseAcute Kidney Injury + DialysisMet SIRS criteria ShockOtherPCR cycle thresholdDate of Initial PCR positive ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download